Boston Scientific (NYSE:BSX) Given New $78.00 Price Target at Robert W. Baird

Key Points

• Robert W. Baird cut its price target on Boston Scientific from $86 to $78 while keeping an "outperform" rating, implying roughly a 20% upside from the prior close.
• Several firms have trimmed price targets after management lowered FY2026 guidance, but analysts remain generally positive — MarketBeat's consensus is a "Moderate Buy" with an average price target of $97.65.
• Boston Scientific beat Q1 estimates with $5.20B revenue (+11.6% YoY) and $0.80 EPS, yet set Q2 guidance of $0.820–0.840 and FY2026 EPS of $3.340–3.410; CEO Michael Mahoney also sold 160,901 shares earlier this year.

Boston Scientific (NYSE:BSX - Get Free Report) had its price target dropped by investment analysts at Robert W. Baird from $86.00 to $78.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage presently has an "outperform" rating on the medical equipment provider's stock. Robert W. Baird's price target points to a potential upside of 20.09% from the stock's previous close.

BSX has been the subject of a number of other research reports. Wall Street Zen cut Boston Scientific from a "buy" rating to a "hold" rating in a report on Saturday, March 28th. Stifel Nicolaus reduced their price target on Boston Scientific from $90.00 to $85.00 and set a "buy" rating for the company in a report on Tuesday. UBS Group reduced their price target on Boston Scientific from $120.00 to $105.00 and set a "buy" rating for the company in a report on Tuesday, March 17th. Raymond James Financial reiterated an "outperform" rating and set a $88.00 price target (down from $97.00) on shares of Boston Scientific in a report on Monday, March 30th. Finally, Truist Financial reduced their price target on Boston Scientific from $90.00 to $85.00 and set a "buy" rating for the company in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat.com, Boston Scientific currently has an average rating of "Moderate Buy" and a consensus price target of $97.65.

Boston Scientific Price Performance

Shares of NYSE BSX opened at $64.95 on Thursday. The stock has a market capitalization of $96.53 billion, a price-to-earnings ratio of 33.48, a PEG ratio of 0.92 and a beta of 0.78. The business has a 50-day moving average of $68.87 and a 200-day moving average of $86.16. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. Boston Scientific has a fifty-two week low of $59.38 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.01. The company had revenue of $5.20 billion during the quarter, compared to analysts' expectations of $5.19 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.Boston Scientific's revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter last year, the company earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, sell-side analysts predict that Boston Scientific will post 3.45 earnings per share for the current fiscal year.

Insider Transactions at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the sale, the chief executive officer owned 1,411,735 shares of the company's stock, valued at $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.34% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Boston Scientific

Large investors have recently added to or reduced their stakes in the stock. Financial Consulate Inc. acquired a new stake in Boston Scientific during the third quarter worth approximately $25,000. Murphy & Mullick Capital Management Corp grew its position in Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider's stock worth $25,000 after buying an additional 170 shares in the last quarter. FWL Investment Management LLC acquired a new stake in Boston Scientific during the second quarter worth approximately $26,000. Swiss RE Ltd. acquired a new position in Boston Scientific during the fourth quarter valued at approximately $26,000. Finally, Garton & Associates Financial Advisors LLC acquired a new position in Boston Scientific during the fourth quarter valued at approximately $26,000. Institutional investors and hedge funds own 89.07% of the company's stock.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q1 beat and strong sales growth: Boston Scientific reported revenue up ~11.6% and adjusted EPS that matched/beat estimates, fueling optimism about underlying demand and prompting the initial rally. Boston Scientific announces results for first quarter 2026
• Positive Sentiment: Unusually heavy bullish options flow: Large volumes of call buying suggest speculative and institutional interest expecting further upside in the near term. Traders Purchase High Volume of Boston Scientific Call Options NYSE: BSX
• Positive Sentiment: Analysts keep conviction despite cuts: Several firms (Jefferies, Barclays) lowered price targets but kept Buy/Overweight calls, framing the guidance cut as a near-term reset rather than a call to sell. Balancing Near-Term Guidance Cuts With Long-Term Growth Drivers: Upholding a Buy on Boston Scientific
• Neutral Sentiment: Stifel trims expectations but keeps Buy: Stifel lowered its price target from $90 to $85 while maintaining a buy rating — a modest downward adjustment that signals cautious optimism. Stifel Nicolaus Has Lowered Expectations for Boston Scientific NYSE: BSX Stock Price
• Neutral Sentiment: Price-target resets across the street: Multiple banks cut targets (Barclays, Jefferies) to reflect the lower 2026 outlook, reducing upside numbers while still often keeping positive ratings — a mixed signal for medium-term momentum. Why Is Boston Scientific Stock Soaring Wednesday?
• Negative Sentiment: Guidance cut and lower 2026 profit forecast: Management trimmed FY2026 EPS and revenue guidance, which is the main driver of analyst revisions and investor caution. Boston Scientific cuts 2026 profit forecast, trims revenue growth view
• Negative Sentiment: Litigation overhang: Multiple law firms have filed/invited claims alleging misstatements tied to past disclosures, creating potential legal and settlement risk and an added source of volatility. BSX DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important May 4 Deadline in Securities Class Action - BSX
• Negative Sentiment: Near-term valuation pressure: Recent analyst downgrades and PT cuts have pushed the shares to new lows at points, reflecting increased caution about near-term growth. Boston Scientific NYSE: BSX Hits New 52-Week Low After Analyst Downgrade

Boston Scientific Company Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.